Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Acquired by ExodusPoint Capital Management LP

ExodusPoint Capital Management LP raised its stake in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 147.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 85,662 shares of the company's stock after acquiring an additional 51,049 shares during the quarter. ExodusPoint Capital Management LP owned approximately 0.11% of Nurix Therapeutics worth $1,614,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. FMR LLC boosted its holdings in Nurix Therapeutics by 675.9% in the third quarter. FMR LLC now owns 586,902 shares of the company's stock worth $13,188,000 after acquiring an additional 511,256 shares in the last quarter. Lord Abbett & CO. LLC acquired a new position in Nurix Therapeutics in the 3rd quarter worth approximately $7,879,000. Vanguard Group Inc. lifted its stake in Nurix Therapeutics by 8.3% during the 4th quarter. Vanguard Group Inc. now owns 4,345,266 shares of the company's stock valued at $81,865,000 after acquiring an additional 333,452 shares during the period. Norges Bank acquired a new position in Nurix Therapeutics during the fourth quarter valued at $6,006,000. Finally, Wellington Management Group LLP raised its stake in shares of Nurix Therapeutics by 8.8% during the 3rd quarter. Wellington Management Group LLP now owns 3,482,105 shares of the company's stock valued at $78,243,000 after buying an additional 280,240 shares during the last quarter.

Nurix Therapeutics Stock Performance

NRIX stock traded up $0.33 during midday trading on Monday, reaching $9.47. 113,061 shares of the company were exchanged, compared to its average volume of 894,620. The stock's 50-day simple moving average is $14.03 and its 200 day simple moving average is $19.16. The company has a market cap of $721.95 million, a price-to-earnings ratio of -3.28 and a beta of 2.23. Nurix Therapeutics, Inc. has a 1-year low of $8.18 and a 1-year high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last posted its earnings results on Tuesday, April 8th. The company reported ($0.67) EPS for the quarter, topping analysts' consensus estimates of ($0.72) by $0.05. The business had revenue of $18.45 million for the quarter, compared to analysts' expectations of $12.78 million. Nurix Therapeutics had a negative return on equity of 53.65% and a negative net margin of 354.85%. During the same quarter in the previous year, the firm earned ($0.76) earnings per share. On average, research analysts anticipate that Nurix Therapeutics, Inc. will post -2.99 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms recently commented on NRIX. HC Wainwright restated a "buy" rating and set a $36.00 price target on shares of Nurix Therapeutics in a research report on Wednesday, April 2nd. Morgan Stanley raised their price objective on Nurix Therapeutics from $16.00 to $17.00 and gave the company an "equal weight" rating in a report on Monday, February 3rd. Leerink Partnrs upgraded Nurix Therapeutics to a "hold" rating in a research report on Monday, March 17th. JPMorgan Chase & Co. cut their price target on shares of Nurix Therapeutics from $31.00 to $30.00 and set an "overweight" rating for the company in a report on Wednesday, January 29th. Finally, Needham & Company LLC dropped their target price on shares of Nurix Therapeutics from $28.00 to $27.00 and set a "buy" rating on the stock in a research report on Wednesday, April 9th. Three equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $30.44.

Insider Activity at Nurix Therapeutics

In other news, insider Gwenn Hansen sold 3,690 shares of the stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $19.85, for a total value of $73,246.50. Following the sale, the insider now directly owns 55,937 shares in the company, valued at $1,110,349.45. This represents a 6.19 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Houte Hans Van sold 5,825 shares of the stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $14.49, for a total value of $84,404.25. Following the sale, the chief financial officer now directly owns 33,724 shares in the company, valued at approximately $488,660.76. The trade was a 14.73 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 12,326 shares of company stock worth $213,449 in the last three months. Insiders own 7.20% of the company's stock.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.